Acute Migraine Treatment Market (By Drug Type: Triptans, CGRP Antagonist, NSAID Drugs, Beta-adrenergic, Ergot Alkaloids, Others, By Route Of Administration: Oral, Injection, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Acute Migraine Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Acute Migraine Treatment Market, by Drug Type, 2024-2034
8.1.1 Triptans
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. CGRP Antagonist
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. NSAID Drugs
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Beta-adrenergic
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Ergot Alkaloids
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Acute Migraine Treatment Market, by Route of Administration, 2024-2034
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Injection
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Acute Migraine Treatment Market, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1. Teva Pharmaceutical
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Hoffmann-La Roche Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson and Johnson
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Amgen
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly & Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample